Bladder cancer: Confirmation of long-term superiority of adjuvant BCG in both intermediate-risk and high-risk patients

摘要

A decade of follow-up has proved that intravesical instillation of bacillus Calmette-Guerin (BCG) following transurethral resection is associated with better outcomes than chemotherapy. Notably, the long-term benefits of adjuvant BCG treatment were evident in patients with intermediate-risk or high-risk stage Ta or T1 bladder cancer. First results from the phase III EORTC Genito-Urinary Group trial 30911 were published in 2001. At that time, BCG was shown to prolong time to first recurrence more efficaciously than the anthracycline epirubicin.